Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia

Journal of Clinical Oncology

Volumn 25, Issue 1, 2007, Pages 25-31

  Giles, Francis J ^a   Rizzieri, David ^b   Karp, Judith ^b   Vey, Norbert ^b   Ravandi, Farhad ^b   Faderl, Stefan ^b   Khan, Khuda Dad ^b   Verhoef, Gregor ^b   Wijermans, Pierre ^b   Advani, Anjali ^b   Roboz, Gail ^b   Kantarjian, Hagop ^b   Bilgrami, Syed Fazl Ali ^b   Ferrant, Augustin ^b   Daenen, Simon M G J ^b   Karsten, Verena ^b   Cahill, Ann ^b   Albitar, Maher ^b   Mufti, Ghulam ^b   O'Brien, Susan ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CLORETAZINE; HYDRAZINE DERIVATIVE; HYDROXYUREA; UNCLASSIFIED DRUG; VNP 4010M; 1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL) 2 ((2 METHYLAMINO)CARBONYL)HYDRAZINE; 1,2-BIS(METHYLSULFONYL)-1-(2-CHLOROETHYL)-2-((2-METHYLAMINO)CARBONYL)HYDRAZINE; SULFONAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG ERUPTION; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PANCYTOPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; CHEMICAL MODEL; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; RISK; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; HYDRAZINES; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MODELS, CHEMICAL; PROGNOSIS; REMISSION INDUCTION; RISK; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846413076     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.0961     Document Type: Article

References (43)

1. Giles FJ, Keating A, Goldstone AH, et al: Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2002:73-110, 2002
2. Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999
3. Rowe JM, Li X, Cassileth PA, et al: Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience. Presented at the American Society of Hematology, New Orleans, LA, December 2-6, 2005. ASH Annual Meeting Abstracts 106:546, 2005
4. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
5. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998
6. Cortes J, Estey E, Beran M, et al: Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 36:479-484, 2000
7. Hall AG, Tilby MJ: Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6:163-173, 1992
8. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31:205-213, 1992
9. Povirk LF, Shuker DE: DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 318:205-226, 1994
10. Lind MJ, Ardiet C: Pharmacokinetics of alkylating agents. Cancer Surv 17:157-188, 1993
11. Shyam K, Cosby LA, Sartorelli AC: Synthesis and evaluation of N,N′-bis(arylsulfonyl)hydrazines as antineoplastic agents. J Med Chem 28:525-527, 1985
12. Shyam K, Hrubiec RT, Furubayashi R, et al: 1,2-Bis(sulfonyl)hydrazines: 3. Effects of structural modification on antineoplastic activity. J Med Chem 30:2157-2161, 1987
13. Penketh PG, Shyam K, Sartorelli AC: Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283-291, 2000
14. Pratviel G, Shyam K, Sartorelli AC: Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer- phenotype. Cancer Biochem Biophys 10:365-375, 1989
15. Finch RA, Shyam K, Penketh PG, et al: 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-(methylamino) carbonylhydrazine (101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033-3038, 2001
16. Ishiguro K, Shyam K, Penketh PG, et al: Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther 4:1755-1763, 2005
17. Shyam K, Penketh PG, Loomis RH, et al: Antitumor2-(aminocarbonyl)-1,2- bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. J Med Chem 39:796-801, 1996
18. Baumann RP, Shyam K, Penketh PG, et al: 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 53:288-295, 2004
19. Mao J, Xu Y, Wu D, et al: Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat. AAPS Pharm-Sci 4:E24, 2002
20. Murren J, Modiano M, Kummar S, et al: A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 23:123-135, 2005
21. Giles F, Thomas D, Garcia-Manero G, et al: A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10:2908-2917, 2004
22. Giles F, Verstovsek S, Thomas D, et al: Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11:7817-7824, 2005
23. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
24. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
25. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
26. Giles F, Verstovsek S, Faderl S, et al: A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 30:1591-1595, 2006
27. Vey N, Giles F: Cloretazine for the treatment of acute myeloid leukemia. Expert Rev Anticancer Ther 6:321-328, 2006
28. Gerson SL, Miller K, Berger NA:O6alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 76:2106-2114, 1985
29. Ishiguro K, Seow HA, Penketh PG, et al: Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 5:969-976, 2006
30. Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307, 2004
31. Spiro TP, Liu L, Majka S, et al: Temozolomide: The effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 7:2309-2317, 2001
32. Liu L, Markowitz S, Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375-5379, 1996
33. Taverna P, Catapano CV, Citti L, et al: Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 3:401-405, 1992
34. Seiter K, Liu D, Loughran T, et al: Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 20:3249-3253, 2002
35. D'Atri S, Piccioni D, Castellano A, et al: Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann Oncol 6:389-393, 1995
36. Giles FJ: New drugs in acute myeloid leukemia. Curr Oncol Rep 4:369-374, 2002
37. Menzin J, Lang K, Earle CC, et al: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597-1603, 2002
38. Lang K, Earle CC, Foster T, et al: Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 22:943-955, 2005
39. Juliusson G, Billstrom R, Gruber A, et al: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 20:42-47, 2006
40. Mengis C, Aebi S, Tobler A, et al: Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21:3933-3939, 2003
41. Giles FJ, Kantarjian HM, Cortes JE, et al: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21:1722-1727, 2003
42. Giles FJ, Kantarjian HM, Cortes JE, et al: Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29:649-652, 2005
43. Solberg LA Jr: Biologic aspects of thrombopoietins and the development of therapeutic agents. Curr Hematol Rep 4:423-428, 2005